Analysis of transcriptional changes associated with acquired resistance to docetaxel in HR+/HER2- breast cancer cell line MCF-7

Large-scale genomic analyses comparing tumors before and after chemotherapy have failed to identify recurrent mutations that consistently account for treatment failure. Instead, resistance is thought to arise predominantly through non-genetic, adaptive mechanisms, including the acquisition of gene expression changes that allow cancer cells to survive chemotherapy-induced stress and later re-enter proliferative programs.To uncover transcriptional adaptations to docetaxel, a chemotherapeutic agent used in the NAC clinical setting, we performed bulk RNA-sequencing on parental and docetaxel-resistant MCF-7 cells.